Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash from Financing Activities (2016 - 2025)

Rein Therapeutics filings provide 9 years of Cash from Financing Activities readings, the most recent being $2.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 240400.0% year-over-year to $2.4 million, compared with a TTM value of $9.8 million through Dec 2025, down 45.25%, and an annual FY2025 reading of $9.8 million, down 45.25% over the prior year.
  • Cash from Financing Activities hit $2.4 million in Q4 2025 for Rein Therapeutics, up from $1.9 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $55.6 million in Q1 2021, with the low at -$446000.0 in Q3 2024.
  • Median Cash from Financing Activities over the past 4 years was $1.3 million (2025), compared with a mean of $8.3 million.
  • The sharpest move saw Cash from Financing Activities plummeted 99.99% in 2024, then soared 240400.0% in 2025.
  • Year by year, Cash from Financing Activities stood at $1000.0 in 2021, then soared by 1579300.0% to $15.8 million in 2023, then crashed by 99.99% to $1000.0 in 2024, then surged by 240400.0% to $2.4 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $2.4 million, $1.9 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.